Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
NCT06506916 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
Conditions Studied
Interventions
- DRUG bimekizumab
Study Locations (16)
Other
- Ps0039 40515 — Berlin
- Ps0039 40287 — Frankfurt am Main
- Ps0039 40072 — Freiburg im Breisgau
- Ps0039 40775 — Witten
- Ps0039 40347 — Lodz
- Ps0039 40757 — Poznan
- Ps0039 40625 — Warsaw
- Ps0039 40761 — Warsaw
- Ps0039 40773 — Wroclaw
California
- Ps0039 50162 — Fountain Valley
- Ps0039 50642 — Santa Monica
Alabama
- Ps0039 50140 — Birmingham
Florida
- Ps0039 50283 — Tampa
Michigan
- Ps0039 50110 — Ann Arbor
New York
- Ps0039 50643 — Rochester
Pennsylvania
- Ps0039 50491 — Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2028-03-14 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06506916
The ClinicalTrials.gov registry entry for NCT06506916 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 116 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention — of which bimekizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06506916 reports 16 study locations spanning 7 distinct geographic areas — top geographies include Other, California, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06506916 about?
NCT06506916 is a clinical study titled "A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biop...
What is the current status of trial NCT06506916?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2024-07-29. Estimated completion is 2028-03-14.
What conditions does trial NCT06506916 study?
This clinical trial studies the following conditions: Psoriatic Arthritis, Moderate to Severe Plaque Psoriasis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06506916?
The interventions under investigation include: bimekizumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06506916?
This trial is sponsored by UCB Biopharma SRL, which has 116 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06506916 being conducted?
This trial has 16 study locations across Alabama, California, Florida, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.